SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.13 CNY | -2.36% |
|
-2.80% | -13.87% |
| Apr. 08 | Shenzhen Xintai Pharmaceutical's Drug to Treat Chronic Heart Failure Set for Clinical Trials | MT |
| Mar. 26 | Salubris Pharma's Profit, Revenue Slip in 2023 | MT |
| Sales 2024 * | 3.92B 542M | Sales 2025 * | 4.74B 655M | Capitalization | 30.7B 4.24B |
|---|---|---|---|---|---|
| Net income 2024 * | 687M 94.89M | Net income 2025 * | 839M 116M | EV / Sales 2024 * | 7.01 x |
| Net cash position 2024 * | 3.2B 442M | Net cash position 2025 * | 3.18B 439M | EV / Sales 2025 * | 5.81 x |
| P/E ratio 2024 * |
47.1
x | P/E ratio 2025 * |
38
x | Employees | 3,517 |
| Yield 2024 * |
1.88% | Yield 2025 * |
1.55% | Free-Float | 38.31% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.36% | ||
| 1 week | -2.80% | ||
| Current month | -3.37% | ||
| 1 month | -0.95% | ||
| 3 months | -2.83% | ||
| 6 months | -2.53% | ||
| Current year | -13.87% |
1 week
27.92
29.77
1 month
27.0229.85
Current year
23.5033.00
1 year
23.5037.31
3 years
20.0039.33
5 years
16.7043.66
10 years
16.7046.32
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Yan
CEO | Chief Executive Officer | 51 | 05-12-31 |
Ai Zhen Li
CHM | Chairman | 54 | 04-02-29 |
Yun Kong
DFI | Director of Finance/CFO | 51 | 21-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Hai Ye
BRD | Director/Board Member | 80 | 98-11-02 |
Sing Ye
CHM | Chairman | 49 | 04-06-30 |
Jian Feng Yang
BRD | Director/Board Member | 48 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.63% | 2 M€ | -20.87% | - | |
| 0.46% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 28.13 | -2.36% | 4,520,709 |
| 24-04-18 | 28.81 | -0.35% | 2,769,126 |
| 24-04-17 | 28.91 | +0.38% | 3,185,464 |
| 24-04-16 | 28.8 | -2.04% | 4,083,569 |
| 24-04-15 | 29.4 | +1.59% | 4,003,109 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides two categories of products: pharmaceutical preparation and bulk drugs. The Company is also engaged in the research and development, production and sales of cardiovascular medical devices. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-22
- Extraordinary Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
28.13
CNY
Average target price
37
CNY
Spread / Average Target
+31.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.87% | 4.34B | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +9.05% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.64% | 5.09B |
- Stock Market
- Equities
- 002294 Stock
